Press Release Details

Cerus Corporation Appoints David N. Cook as Vice President, Biotherapeutic Research and Development

October, 04 2001
Cerus Corporation (Nasdaq: CERS) today announced the appointment of David N. Cook, Ph.D., to the position of vice president, Biotherapeutic Research and Development. Dr. Cook, an accomplished scientist and proven medical products executive, rejoins Cerus with over 11 years of research and development experience, specifically in the area of transfusion medicine, oncology and stem cell transplantation. In this newly-created position, Dr. Cook will lead the company's development of biotherapeutic products.

“We are extremely pleased to have Dr. Cook, with his extensive product and business development experience, return to our management team,” said Stephen T. Isaacs, president and chief executive officer of Cerus. “While we remain focused on the near-term commercialization of our INTERCEPT Blood Systems for inactivating pathogens in blood, we believe it is essential to build our product pipeline to sustain our future growth. Dr. Cook will focus his efforts on leveraging the therapeutic potential of our proprietary Helinx technology. He will also evaluate other opportunities that complement our existing scientific and development expertise and address significant unmet medical needs.”

Dr. Cook, 43, joins Cerus from Eligix Incorporated where he held the position of senior vice president of Research and Development. Under his leadership the company gained European approval for their BCell-HDM and Tcell-HDM devices, medical products developed to improve the outcome of stem cell transplantation. Prior to Eligix, Dr. Cook was the vice president of Commercialization and the director of Red Cell Development for Cerus Corporation. Dr. Cook also spent three years as a postdoctoral scientist for the Lawrence Berkeley National Laboratory, where he studied DNA supercoiling and discovered genes in bacteria important in drug resistance. He holds an A.B. in American Studies from Harvard University, a B.S. in Chemistry from California State University, Long Beach, and a Ph.D. in Chemistry from the University of California, Berkeley.


Cerus Corporation is developing medical systems and therapeutics based on its proprietary Helinx™ technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of the blood products used for transfusion. These INTERCEPT Blood Systems, based on the company's Helinx technology, are designed to inactivate viruses, bacteria, other pathogens and white blood cells. The Concord, California-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases. Helinx is a trademark of Cerus Corporation

INTERCEPT Blood System is a trademark of Baxter International, Inc. (NYSE: BAX)

Statements in this news release regarding product development and product potential are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the risks and uncertainty of the timing and results of clinical trials and other development activities, actions by regulatory authorities at any stage of the development process, additional financing activities, market acceptance of any products, competitive conditions and other factors discussed in the company's most recent reports on Forms 10K, 10Q and other filings with the Securities and Exchange Commission.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600